Investor Relations - Curis

Investor Alerts

Oct 25, 2007

Curis Announces Presentation at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 25, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
Oct 23, 2007

Curis to Release Third Quarter 2007 Financial Results and Hold Conference Call on October 30, 2007

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 23, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, will...
Oct 17, 2007

Curis Announces Presentation at CHI's ''Discovery on Target: Developing Inhibitors for Promising Drug Targets'' Conference

Curis Presents Preclinical Data on CUDC-101

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 17, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
Oct 16, 2007

Curis, Inc. Announces Initiation of Expansion Cohort in Collaborator Genentech's Phase I Clinical Trial of a Systemically Administered Hedgehog Antagonist

Curis to receive $3 million payment

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 16, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
Oct 1, 2007

Curis to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

CAMBRIDGE, Mass., Oct 31, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...

Show per page